News

15

Feb
A joint press release between I-MAK, DNP+ and MSF Access Campaign on challenges to patents (patent oppositions) was filed in India on key hep C drugs sofosbuvir, daclatasvir and velpatasvir. New Delhi/New York, 14 February 2017–Five new challenges against patents on crucial new medicines to treat ...

29

Mar
For pricing and availability of generic Indian daclatasvir as on 7 March 2016, Please click here.

08

Mar
For a simplified snapshot from TREAT Asia/amfAR on ledipasvir and sofosbuvir co-formulation for the treatment of hepatitis C, please click here.

24

Feb
For a simplified snapshot from TREAT Asia/amfAR on daclatasvir, a second generation direct-acting antiviral for the treatment of hepatitis C, please click here.